Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

No-Needle cancer test: ultrasound reads tumor type

NCT ID NCT07581054

Diagnosis Sponsor: Anhui Provincial Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to tell breast cancer types apart using a special ultrasound, instead of a tissue biopsy. Researchers looked at blood vessel patterns in tumors from 94 patients and built a tool to predict whether the cancer was luminal or non-luminal. The goal is to help doctors choose the best treatment without needing to take a sample from the tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

94 people

The number who actually took part.

Started

May 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 94 consecutive patients with histologically confirmed invasive breast cancer who underwent super-resolution ultrasound (SRUS) at the First Affiliated Hospital of USTC (Anhui Provincial Cancer Hospital) between May 2025 and January 2026 were included. All patients had available immunohistochemical data for molecular subtyping (ER, PR, HER2, Ki-67) according to the St. Gallen criteria. The cohort comprised 64 patients with luminal subtype and 30 patients with non-luminal subtype. Key demographic and clinical characteristics (age, tumor size, menopausal status) were balanced between the two groups.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥ 18 years Histologically confirmed invasive breast cancer Underwent super-resolution ultrasound (SRUS) examination between May 2025 and January 2026 Available immunohistochemical data (estrogen receptor, progesterone receptor, HER2, and Ki-67) for molecular subtyping according to the St. Gallen International Expert Consensus Exclusion Criteria: Prior treatment for ipsilateral breast cancer Pregnancy or lactation Severe cardiac, hepatic, or renal insufficiency Psychiatric disorder Inadequate ultrasound image quality precluding reliable SRUS reconstruction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.